Why evaluate MDR1 receptor affinity in CNS pharmacokinetic assays?

6 April 2021
Communications Department

The pharmacological implications in blood-brain barrier permeability assays.

Drug delivery to the brain is a challenging evaluation to consider during novel compounds discovery stages to study central nervous pharmacokinetics in terms of efficacy and safety.

This is the fact to the specialized cellular integration of the blood-brain barrier (BBB) and their interaction with additional perivascular elements form a highly selective barrier that regulates substance movement in and out the Central Nervous System (CNS).

In the case of large molecules, movement across the BBB is dependent of carrier mediated transporters such as the multidrug resistance (MDR1) gene product, P-glycoprotein (Pgp) which according to the scientific community and main regulatory agencies, is considered the reference efflux transporter at the CNS barrier site, due to its pharmacological relevance.

In this context, it is, of tremendous importance to ascertain whether new molecular entities (NMEs) are potential substrates of P-gp in order to accurately predict their pharmacokinetics in the CNS at the early stages of drug discovery.

Following FDA recommendations, ReadyCell scientists have developed a cell-based model system to reliably predict P-pg-mediated drug interactions in the CNS. In addition, this cellular model which consists of Madin-Darby Canine Kidney (MDCKII) cells overexpressing the MDR1 gene product (P-pg) when combined with a patented Shipping Medium is able to be transported worldwide in a ready-to-use format.

Based on the scientific literature, we highlight the permeability values (Papp)  of a data set of 7 marketed CNS drugs tested in the MDCKII-MDR1 cell model system.

Alprenolol Transcellular 53 +/- 7
Atenolol Paracellular 0,7 +/- 0.2
Baclofen Paracellular/Influx 0,7 +/-0,4
Diazepam Transcellular 65 +/- 18
Metronidazole Transcellular 11
Midazolam Transcellular 42 +/- 6
Propanolol Transcellular 38-50
Table 1. Unidirectional Permeability Assay values (Papp)x106 (cm/s) in MDCKII-MDR1 cell model.


In case you are developing NMEs with the mechanism of action based on CNS, we advise you to consult our product portfolio specially designed for and contact our specialists at reagents@readycell.com.

Related posts

Cancer drug development: what to know about ABC transporters

Cancer drug development: what to know about ABC transporters

The presence of the superfamily members of the ATP binding cassette (ABC) transporters is well established as the main cause of multidrug resistance, since they efflux therapeutic compounds from cells and reduce the intracellular drug levels.

A new study uses CacoGoblet in a gut-liver-organ-on-a-chip

A new study uses CacoGoblet in a gut-liver-organ-on-a-chip

An investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. The CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).

Caco-2 Permeability Assay Protocol

Caco-2 Permeability Assay Protocol

Caco-2 cells assay is a reference assayto evaluate intestinal permeability in drug discovery stages, optimizing novel compounds screening.